These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 37274252)

  • 1. Deciphering immune microenvironment and cell evasion mechanisms in human gliomas.
    Rafii S; Kandoussi S; Ghouzlani A; Naji O; Reddy KP; Ullah Sadiqi R; Badou A
    Front Oncol; 2023; 13():1135430. PubMed ID: 37274252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune response in glioma's microenvironment.
    Chen H; Li M; Guo Y; Zhong Y; He Z; Xu Y; Zou J
    Innov Surg Sci; 2020 Dec; 5(3-4):20190001. PubMed ID: 33511267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune microenvironment of gliomas.
    Gieryng A; Pszczolkowska D; Walentynowicz KA; Rajan WD; Kaminska B
    Lab Invest; 2017 May; 97(5):498-518. PubMed ID: 28287634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas.
    Chen S; Zhang S; Wang Z; Li J; Yuan Y; Li T; Zuo M; Feng W; Li W; Chen M; Liu Y
    Front Pharmacol; 2022; 13():1038272. PubMed ID: 36438805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glioma-Immune Cell Crosstalk in Tumor Progression.
    Elguindy M; Young JS; Mondal I; Lu RO; Ho WS
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of myeloid cells in the immunosuppressive microenvironment in gliomas.
    Locarno CV; Simonelli M; Carenza C; Capucetti A; Stanzani E; Lorenzi E; Persico P; Della Bella S; Passoni L; Mavilio D; Bonecchi R; Locati M; Savino B
    Immunobiology; 2020 Jan; 225(1):151853. PubMed ID: 31703822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research Progress in Immunotherapy of Gliomas.
    Duan ZH; Wei ZL
    J Integr Neurosci; 2023 Aug; 22(5):118. PubMed ID: 37735122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma.
    Zeng F; Li G; Liu X; Zhang K; Huang H; Jiang T; Zhang Y
    Oncologist; 2021 Aug; 26(8):e1460-e1469. PubMed ID: 33687124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Infiltrating Cells-Derived Risk Signature Based on Large-scale Analysis Defines Immune Landscape and Predicts Immunotherapy Responses in Glioma Tumor Microenvironment.
    Zhang N; Zhang H; Wang Z; Dai Z; Zhang X; Cheng Q; Liu Z
    Front Immunol; 2021; 12():691811. PubMed ID: 34489938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer Metabolism: The Role of Immune Cells Epigenetic Alteration in Tumorigenesis, Progression, and Metastasis of Glioma.
    Kanwore K; Kanwore K; Adzika GK; Abiola AA; Guo X; Kambey PA; Xia Y; Gao D
    Front Immunol; 2022; 13():831636. PubMed ID: 35392088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis prediction and tumor immune microenvironment characterization based on tryptophan metabolism-related genes signature in brain glioma.
    Zhang S; Chen S; Wang Z; Li J; Yuan Y; Feng W; Li W; Chen M; Liu Y
    Front Pharmacol; 2022; 13():1061597. PubMed ID: 36386216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
    Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
    Front Neurol; 2022; 13():977180. PubMed ID: 36353126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of cuproptosis-related genes signature and its impact on the reshaped immune microenvironment of glioma.
    Chen S; Zhang S; Yuan Y; Wang Z; Li J; Li T; Zuo M; Feng W; Chen M; Liu Y
    Front Pharmacol; 2022; 13():1016520. PubMed ID: 36267281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments.
    Alghamri MS; McClellan BL; Hartlage CS; Haase S; Faisal SM; Thalla R; Dabaja A; Banerjee K; Carney SV; Mujeeb AA; Olin MR; Moon JJ; Schwendeman A; Lowenstein PR; Castro MG
    Front Pharmacol; 2021; 12():680021. PubMed ID: 34084145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas.
    Tu Z; Ji Q; Han Q; Long X; Li J; Wu L; Huang K; Zhu X
    BMC Cancer; 2022 Sep; 22(1):973. PubMed ID: 36096781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma.
    Yan D; Li W; Liu Q; Yang K
    Front Immunol; 2022; 13():914618. PubMed ID: 35769466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploitation of immune mechanisms in the treatment of central nervous system cancer.
    Pollack IF; Okada H; Chambers WH
    Semin Pediatr Neurol; 2000 Jun; 7(2):131-43. PubMed ID: 10914414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Siglec10-An immunosuppressor and negative predictor of survival prognosis in gliomas.
    Wang H; Feng Y; Zhang Y; Wang T; Xu H; Zhi Y; Feng Y; Tian L; Yuan K
    Front Genet; 2022; 13():873655. PubMed ID: 36468012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PDIA5 is Correlated With Immune Infiltration and Predicts Poor Prognosis in Gliomas.
    Zhang H; He J; Dai Z; Wang Z; Liang X; He F; Xia Z; Feng S; Cao H; Zhang L; Cheng Q
    Front Immunol; 2021; 12():628966. PubMed ID: 33664747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.
    Lefranc F; Rynkowski M; DeWitte O; Kiss R
    Adv Tech Stand Neurosurg; 2009; 34():3-35. PubMed ID: 19368079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.